Priavoid

A life without dementia

Priavoid

A life without dementia

Our Vision

Priavoid wants to stop Alzheimer’s disease using a new treatment strategy with a new class of orally available compounds. In parallel, this new treatment strategy will be applied to other neurodegenerative diseases.

Latest Press Releases: Priavoid started the first-in-human, first-in-class phase I-study of PRI-002 on April 16th 2018. A Phase II clinical trial is in preparation and scheduled to start in 2019.

Therapeutic Approach

Alzheimer’s disease occurs because harmless protein molecules, so-called monomers, clump into harmful toxic oligomers and damage nerve cells. The harmless monomers are constantly produced in all human beings without leading to disease. The toxic oligomers form rarely and kind of randomly, but if one waits long enough, they will form for sure. This is presumably the reason, why age is the highest risk factor for Alzheimer’s. 

Many research groups, as well as the pharmaceutical industry, are trying to reduce the production of the monomers in order to preventively decrease the probability of oligomer formation. Some few approaches attempt to label the oligomers with specific antibodies hoping that components of the immune system are able to deplete the oligomers. Our therapy strategy, however, is completely different. With our especially developed drug candidate we aim to target and directly eliminate already formed oligomers without the need to rely on the help of the immune system.

The positive results of all of our previous studies in several animal models have led us to take the next step towards a clinical study.

Priavoid has deep experience in research, pharma, and business development

Get in Touch

Privacy Policy*

8 + 4 =

Priavoid GmbH
Theodor-Heuss-Str. 179
52428 Jülich
Germany

Telephone: +49 (0) 2461 61-2100
Telefax: +49 (0) 2461 61-2023
Mail: info@priavoid.com

Click on the button below to load the content of Google Maps.
Load content

PGlmcmFtZSBzcmM9Imh0dHBzOi8vd3d3Lmdvb2dsZS5jb20vbWFwcy9lbWJlZD9wYj0hMW0xNCExbTghMW0zITFkNDk5NC42ODM3NTUwNDYwNzUhMmQ2LjMxMzg2NTI1ODY1MTk3ITNkNTAuOTI5MDM5Nzg0NDk2OTE1ITNtMiExaTEwMjQhMmk3NjghNGYxMy4xITNtMyExbTIhMXMweDQ3YmY1OTJhMzY2MjA1YzElM0EweGI1ZmNlODQ0YjRiMjkzM2UhMnNUaGVvZG9yLUhldXNzLVN0cmElQzMlOUZlKzE3OSUyQys1MjQyOCtKJUMzJUJDbGljaCE1ZTAhM20yITFzZGUhMnNkZSE0djE1MjcxNjkyOTQ1NjEiIHdpZHRoPSI0MDAiIGhlaWdodD0iMTU1IiBmcmFtZWJvcmRlcj0iMCIgc3R5bGU9ImJvcmRlcjowIiBhbGxvd2Z1bGxzY3JlZW4+PC9pZnJhbWU+

Cookie Preference

Please select an option. You can find more information about the consequences of your choice at Help.

Select an option to continue

Your selection was saved!

Help

Help

To continue, you must make a cookie selection. Below is an explanation of the different options and their meaning.

  • Accept all cookies:
    All cookies such as tracking and analytics cookies.
  • Accept first-party cookies only:
    Only cookies from this website.
  • Reject all cookies:
    No cookies except for those necessary for technical reasons are set.

You can change your cookie setting here anytime: Privacy Policy. Legal Notice

Back